Showing 6041-6050 of 9397 results for "".
- Survey Findings: Submental Region Major Pain Point for Patientshttps://practicaldermatology.com/news/survey-findings-submental-region-major-pain-point-for-patients/2458247/Close to 50 percent of individuals are bothered by the appearance of the area under their chin, and many alter their behavior as a result, according to a new survey commissioned by
- Pershing Square Capital Management, L.P. Announces Sale of Its Investment In Valeant Pharmaceuticals International, Inc.https://practicaldermatology.com/news/pershing-square-capital-management-lp-announces-sale-of-its-investment-in-valeant-pharmaceuticals-international-inc/2458249/Pershing Square Capital Management, L.P. (“Pershing Square”) announced today that it has sold its investment in Valeant Pharmaceuticals International, Inc. (“Valeant”) (ticker: NYSE: VRX). Pershing Square CEO Bill Ackman and Vice Chairman Steve Fraidin will remain on the V
- ADAM Names Lori Skraba 2017 Practice Manager of the Yearhttps://practicaldermatology.com/news/adam-names-lori-skraba-2017-practice-manager-of-the-year/2458248/The Association of Dermatology Administrators and Managers (ADAM) named Lori Skraba of DuBois Dermatology and Cosmetics in DuBois, Pa., the recipient of the annual Practice Manager of the Year award. She was recognized at the 25th annual ADAM meeting in Orlando, FL. The ADAM Practice
- Seventeen Percent of Teens Report Excessive Sweatinghttps://practicaldermatology.com/news/seventeen-percent-of-teens-report-excessive-sweating/2458251/More teens than previously thought may experience excessive, uncontrollable sweating, according to data collected by International Hyperhidrosis Society researchers and presented at the recent American Academy of Dermatology’s (AAD) 2017 Annual Me
- Serlopitant May Stop the Itch of Prurigo Nodularishttps://practicaldermatology.com/news/serlopitant-may-stop-the-itch-of-prurigo-nodularis/2458252/Menlo Therapeutics Inc.’s Serlopitant performed well in phase 2 trial (TCP-102) evaluating it as a treatment of pruritus associated with prurigo nodularis, successfully meeting its primary efficacy endpoint and key sec
- New Research Closes In On Personalized AD Therapyhttps://practicaldermatology.com/news/new-research-closes-in-on-personalized-therapy-for-ad/2458254/New research on skin lipids may pave the way toward personalized therapies for atopic dermatitis. Researchers can now identify the precise lipids found in the skin of people who have atopic dermatitis, and compare them to people with healthy skin. Here’s how: A type of tape can pull
- Mosquito Virus Expert Discusses a Promising New Drug For Zikahttps://practicaldermatology.com/news/mosquito-virus-expert-discusses-a-promising-new-drug-for-zika/2458257/Thomas Voss, PhD, a world-renowned leader in infectious disease research, and his team, say there are two strategies for developing a defense program against Zika infection: prevention, achieved by developing an effective vaccine and vaccination program or the development of a drug that can kill
- Pierre Fabre and Hill Dermaceuticals Partner in Commercial Partnership for TOLAK for AKshttps://practicaldermatology.com/news/pierre-fabre-and-hill-dermaceuticals-partner-in-commercial-partnership-for-tolak-for-aks/2458258/Pierre Fabre Dermo-Cosmetique and Hill Dermaceuticals, Inc. have entered into a strategic commercial partnership for TOLAK, a patented prescription dermatologic drug, indicated for the topical treatment of actinic keratosis lesions of the face, ears, and/or scalp. Under the terms of the a
- Sandoz Proposed Biosimilar Shows Equivalent Efficacy to Humirahttps://practicaldermatology.com/news/sandoz-proposed-biosimilar-shows-equivalent-efficacy-to-humira/2458256/Sandoz’s proposed biosimilar adalimumab (GP2017) shows equivalent efficacy to reference medicine, according to data presented at the American Academy of Dermatology (AAD) in Orlando, Florida. The primary endpoint of the study was the proportio
- Zeltiq Shines Spotlight on CoolAdvantage Petite Applicator at AAD Annual Meetinghttps://practicaldermatology.com/news/zeltiq-shines-spotlight-on-coolmini-applicator-at-aad-annual-meeting/2458259/ZELTIQ® Aesthetics is showcasing the CoolAdvantage Petite™ applicator at the American Academy of Dermatology Annual Meeting (AAD) in Orlando. The CoolAdvantage technology is the only non-invasive fat removal technology cleared by the Food and Drug Administration (F